Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.04. | Eliem Therapeutics agrees to acquire Tenet | 4 | Pharmaceutical Technology | ||
11.04. | Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal | 2 | Benzinga.com | ||
11.04. | Eliem Therapeutics to Acquire Tenet Medicines | 1 | Contract Pharma | ||
11.04. | Double autoimmune acquisitions as Century, Eliem each pick up peers | 1 | FierceBiotech | ||
11.04. | Pre-market Movers: Rallybio, Eliem Therapeutics, Alpine Immune Sciences, Rent the Runway, Meiwu Technology | 362 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.55 A.M. ET).In the Green Rallybio Corporation (RLYB) is up over 90% at $3.10.
Eliem... ► Artikel lesen | |
11.04. | Eliem Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | Eliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-market | 2 | RTTNews | ||
11.04. | Eliem Therapeutics to buy Tenet, announces $120 million private placement | 2 | Seeking Alpha | ||
11.04. | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement | 124 | GlobeNewswire (Europe) | Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents... ► Artikel lesen | |
19.03. | Eliem cuts in on Tango, proposing acquisition after strategic review | 2 | FierceBiotech | ||
14.11.23 | Eliem Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
20.07.23 | Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic Alternatives | 349 | GlobeNewswire (Europe) | SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status... ► Artikel lesen | |
11.05.23 | Eliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights | 423 | GlobeNewswire (Europe) | Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 86,65 | +0,64 % | BioNTech: Bringen Sie sich in Sicherheit! | Zahlreiche Nackenschläge müssen heute die Anteilseigner von BioNTech hinnehmen. Denn die Aktie stürzt mit einem Minus von rund zwei Prozent regelrecht ab. Ein Anteilsschein ist damit nur 80,85 EUR wert.... ► Artikel lesen | |
CUREVAC | 2,922 | +0,62 % | CureVac Aktie: Talfahrt setzt sich fort | CureVac-Aktien verzeichnen weiterhin einen negativen Trend. Der Kurs der Aktie liegt aktuell bei 2,16 €, was einem Rückgang von 0,55% in der vergangenen Woche entspricht. Investoren zeigen sich zunehmend... ► Artikel lesen | |
MODERNA | 116,40 | +0,22 % | Moderna-Aktie heute stark gefragt: Kurs legt deutlich zu (104,5278 €) | Zu den großen Gewinnern an der Börse zählt heute die Aktie von Moderna . Der Kurs des Wertpapiers legt kräftig zu. Grund zur Freude haben Aktionäre von Moderna: Die Aktie weist derzeit eine Verteuerung... ► Artikel lesen | |
EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 895,20 | +0,67 % | Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.The company's earnings... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,980 | -2,00 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
GINKGO BIOWORKS | 0,946 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
BEAM THERAPEUTICS | 23,130 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,840 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
ONCOLYTICS BIOTECH | 1,080 | -0,92 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
ASSERTIO | 1,025 | 0,00 % | Assertio Holdings Q1 2024 Earnings Preview | ||
ARCTURUS THERAPEUTICS | 27,270 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
SIGA TECHNOLOGIES | 10,150 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
MERRIMACK PHARMACEUTICALS | 15,000 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
VIR BIOTECHNOLOGY | 10,390 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen |